You are here

  • Home
  • Online First
  • Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Article info

Article menu

other Versions

Download PDFPDF
Clinical trial
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Authors

  1. Correspondence to Dr W J van Driel, Department of Gynaecology, Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066 CX, The Netherlands; w.v.driel{at}nki.nl
View Full Text

Citation

Koole S, van Stein R, Sikorska K on behalf of the OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group, et al
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial
International Journal of Gynecologic Cancer Published Online First: 23 March 2020. doi: 10.1136/ijgc-2020-001231

Publication history

  • Accepted February 13, 2020
  • First published March 23, 2020.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.